Pretransplant Serum Fibrinogen Level may be a Predictive Marker on Chronic Graft-Versus-Host Disease (cGVHD) in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

MANDACI ŞANLI N., Keklik M., Unal A.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.32, sa.1, ss.8-15, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.4999/uhod.225936
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.8-15
  • Anahtar Kelimeler: Allogeneic Hematopoietic Stem Cell Transplantation, Fibrinogen, Inflammation, Chronic Graft-Versus-Host Disease, PROGNOSTIC-SIGNIFICANCE, CHRONIC GVHD, FIBROSIS, MURINE, CANCER, MECHANISMS, PREVENTION, CARCINOMA, BIOLOGY, ROLES
  • Erciyes Üniversitesi Adresli: Evet

Özet

Inflammatory processes play an important role in the pathophysiology of cGVHD. Serum fibrinogen is a proinflammatory protein with a wide range of functions in inflammation. But its role in GVHD is unclear. The aim of this study was to evaluate the predictive impact of pre-transplantation fibrinogen levels on cGVHD in allo-HSCT recipients. We retrospectively analyzed 249 patients with hematologic diseases undergoing allo-HSCT from 10/10 HLA-matched donors. Serum high fibrinogen levels at the time of HSCT (day 0) were significantly associated with cGVHD development in univariate analyses (OR 2.01, p= 0.012) and multivariate analyses (OR 1.003, p= 0.037). There was no significant association between fibrinogen levels and overall survival, disease-free survival and, acute GVHD (p> 0.05). This is the first report demonstrating the association between high fibrinogen levels and increased cGVHD occurrence.Further studies are warranted and may identify the efficacy of fibrinogen as a predictive marker on cGVHD in allo-HSCT recipients.